Monoclonal antibody treatment options for Gram-negative respiratory infections
| Target | Gram-negative target(s) | Development phase | Studied place in therapy | |
| A1102 | LPS-O-antigen D-galactan-III | K. pneumoniae | Pre-clinical | Prevention |
| A1124 | LPS-O-antigen o25b | E. coli | Pre-clinical | Prevention |
| AR-101 | LPS 011 exopolysaccharide | P. aeruginosa | Phase II | Treatment |
| AR-105 | Alginate exopolysaccharide | P. aeruginosa | Phase II | Prevention and treatment |
| Anti-Hyr1 | Hyr1 peptide 5 | A. baumannii and K. pneumoniae | Pre-clinical | Prevention |
| KB001-A | Pcrv protein | P. aeruginosa | Phase II/III | Prevention |
| MEDI3902 | Pcrv protein and Psl exopolysaccharide | P. aeruginosa | Phase II | Prevention |
LPS: lipopolysaccharide; K. pneumoniae: Klebsiella pneumoniae; E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii.